Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P
Target Price
The average target price of ONCOZ.ST is 12 and suggests 94% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell